-
Pas de deux: the coordinated coupling of erythroid differentiation with the cell cycle. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2024-02-19 Merav Socolovsky
Recent work reveals that cell cycle duration and structure are remodeled in lock-step with distinct stages of erythroid differentiation. These cell cycle features have regulatory roles in differentiation, beyond the generic function of increasing cell number.
-
Circulating endothelial cells in pathophysiology. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2024-02-16 Victor Emmanuel Brett, Francoise Dignat George, Chloe James
The purpose of this review is to synthesize recent insights into the roles and importance of circulating endothelial cells (CECs) as indicators of the severity, progression, and prognosis of vascular-related diseases.
-
Generation of red blood cells from induced pluripotent stem cells. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2024-02-14 Naomi Gunawardena, Stella T Chou
Human induced pluripotent stem cells (iPSCs) are an attractive source to generate in-vitro-derived blood for use as transfusable and reagent red cells. We review recent advancements in the field and the remaining limitations for clinical use.
-
Venous thromboembolism: diagnostic advances and unaddressed challenges in management. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2024-02-13 Rick Mathews, Monica T Hinds, Khanh P Nguyen
This review summarizes recent advances in developing targeted diagnostics for venous thromboembolism (VTE) and unaddressed knowledge gaps in patient management. Without addressing these critical data needs, the morbidity in VTE patients will persist.
-
Developmental regulation of primitive erythropoiesis. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2024-02-12 Marlies P Rossmann, James Palis
In this review, we present an overview of recent studies of primitive erythropoiesis, focusing on advances in deciphering its embryonic origin, defining species-specific differences in its developmental regulation, and better understanding the molecular and metabolic pathways involved in terminal differentiation.
-
Hematopoietic stem cell collection for sickle cell disease gene therapy. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2024-02-12 Alexis Leonard, Mitchell J Weiss
Gene therapy for sickle cell disease (SCD) is advancing rapidly, with two transformative products recently approved by the US Food and Drug Administration and numerous others under study. All current gene therapy protocols require ex vivo modification of autologous hematopoietic stem cells (HSCs). However, several SCD-related problems impair HSC collection, including a stressed and damaged bone marrow
-
Macrocytic anemias. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2024-02-08 Mark J Koury, Daniel J Hausrath
Over the last century, the diseases associated with macrocytic anemia have been changing with more patients currently having hematological diseases including malignancies and myelodysplastic syndrome. The intracellular mechanisms underlying the development of anemia with macrocytosis can help in understanding normal erythropoiesis. Adaptations to these diseases involving erythroid progenitor and precursor
-
Signaling networks guiding erythropoiesis. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2024-02-08 Shilpa Kuttikrishnan, Kirti S Prabhu, Abdul Q Khan, Shahab Uddin
Cytokine-mediated signaling pathways, including JAK/STAT, PI3K/AKT, and Ras/MAPK pathways, play an important role in the process of erythropoiesis. These pathways are involved in the survival, proliferation, and differentiation function of erythropoiesis.
-
A role of platelet C-type lectin-like receptor-2 and its ligand podoplanin in vascular biology. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2024-02-07 Katsue Suzuki-Inoue, Nagaharu Tsukiji
Platelets are essential for hemostasis and are also vital in lymphatic and lung development and the maintenance of vascular integrity. Platelet activation receptor C-type lectin-like receptor 2 (CLEC-2) and its endogenous ligand podoplanin (PDPN) in lymphatic endothelial cells (LECs) and other cells regulate these processes. This review aims to comprehensively summarize the roles of platelet CLEC-2
-
microRNAs and thrombo-inflammation: relationship in sight. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2024-01-25 Sonia Aguila, Rocio Gonzalez-Conejero, Constantino Martinez
Thrombo-inflammation is a multifaceted pathologic process involving various cells such as platelets, neutrophils, and monocytes. In recent years, microRNAs have been consistently implicated as regulators of these cells.
-
Vascular microphysiological systems. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2024-01-19 Sarah E Shelton
This review summarizes innovations in vascular microphysiological systems (MPS) and discusses the themes that have emerged from recent works.
-
Age-related micro-environmental changes as drivers of clonal hematopoiesis. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-12-18 Tal Bacharach, Nathali Kaushansky, Liran I Shlush
Both aging and reduced diversity at the hematopoietic stem cells (HSCs) level are ubiquitous. What remains unclear is why some individuals develop clonal hematopoiesis (CH), and why does CH due to specific mutations occur in specific individuals. Much like aging, reduced diversity of HSCs is a complex phenotype shaped by numerous factors (germline & environment). The purpose of the current review is
-
Disparities in acute myeloid leukemia treatments and outcomes. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-12-08 Ann-Kathrin Eisfeld
This review aims to summarize different contributors to survival disparities in acute myeloid leukemia (AML) patients. The focus is set on African-American (hereafter referred to as Black) patients, with separate consideration of self-reported race and ancestry. It aims to also highlight the interconnectivity of the different features that impact on despair survival.
-
The future of HOXA-expressing leukemias: Menin inhibitor response and resistance. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-11-24 Daniela V Wenge, Scott A Armstrong
We provide an update on the successes and ongoing challenges of Menin inhibition as a novel approach for the treatment of patients with acute leukemias that express HOXA cluster genes including leukemias with KMT2A-rearrangements, NPM1 mutations or NUP98-rearrangements. Initial clinical trials show promising response rates in heavily pretreated patients suggesting these inhibitors may have a significant
-
Pediatric acute myeloid leukemia - novel approaches. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-11-21 Seth E Karol,Gwenaelle Gueguen
PURPOSE OF REVIEW Despite higher remission and survival rates than observed in adults, children with acute myeloid leukemia (AML) still suffer unacceptably high rates of treatment failure and late toxicities. Ongoing work aims to improve these long-term outcomes through improvements in the utilization of current therapies, the incorporation of novel chemotherapy agents, and improved use of current
-
Platelet lifespan and mechanisms for clearance. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-10-31 Olga An,Carsten Deppermann
PURPOSE OF REVIEW Activated or aged platelets are removed from circulation under (patho)physiologic conditions, the exact mechanism of platelet clearance under such conditions remains unclear and are currently being investigated. This review focuses on recent findings and controversies regarding platelet clearance and the disruption of platelet life cycle. RECENT FINDINGS The platelet life span is
-
Platelet mechanosensing as key to understanding platelet function. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-10-17 Ingmar Schoen, Martin Kenny, Smita Patil
This review highlights how the perception of platelet function is evolving based on recent insights into platelet mechanobiology.
-
Modelling arterial thrombus formation in vitro. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-10-13 Amelia Drysdale, Azziza Zaabalawi, Sarah Jones
Models of arterial thrombus formation represent a vital experimental tool to investigate platelet function and test novel antithrombotic drugs. This review highlights some of the recent advances in modelling thrombus formation in vitro and suggests potential future directions.
-
Factor XI as a therapeutic target in neuroinflammatory disease. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-09-06 Berk Taskin, Tia C L Kohs, Joseph J Shatzel, Cristina Puy, Owen J T McCarty
This review summarizes the pathophysiology and potential therapeutic options for treatment of multiple sclerosis, a common neuronal demyelinating disorder affecting 2.2 million people worldwide. As an autoimmune disorder, multiple sclerosis is associated with neuroinflammation and increased permeability of the blood-brain barrier (BBB), although the cause linking multiple sclerosis with compromised
-
Mixed donor chimerism following stem cell transplantation for sickle cell disease. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-09-01 Niketa C Shah, Hemalatha G Rangarajan, Alexander Ngwube, Shalini Shenoy
Sickle cell disease is a debilitating hemoglobinopathy with high morbidity and mortality. Hematopoietic stem cell transplantation (HCT) is curative, but the presence of mixed donor/recipient chimerism post-HCT raises concerns about disease control long-term. Mixed donor/recipient chimerism is reported in significant numbers even after aggressive HCT conditioning regimens. Post-HCT, adequacy of donor
-
The immunology of PF4 polyanion interactions. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-08-22 Anh T P Ngo, Veronica Bochenek, Kandace Gollomp
Platelet factor 4 (PF4, CXCL4), the most abundant α-granule platelet-specific chemokine, forms tetramers with an equatorial ring of high positive charge that bind to a wide range of polyanions, after which it changes conformation to expose antigenic epitopes. Antibodies directed against PF4 not only help to clear infection but can also lead to the development of thrombotic disorders such as heparin-induced
-
Novel approaches to measure transfusion effectiveness. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-08-21 Marianne Elaine McPherson Yee, Ross M Fasano
This review encompasses different considerations of transfusion effectiveness based upon clinical scenario and transfusion indication. Tissue oxygenation, cerebral metabolic oxygen use, and red blood cell (RBC) survival are important elements of transfusion effectiveness in individuals with acute and chronic transfusion requirements.
-
Inflammation and bone marrow fibrosis: novel immunotherapeutic targets. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-08-03 Francesca Rossella Calledda, Alessandro Malara, Alessandra Balduini
Myelofibrosis (MF) is primarily driven by constitutive activation of the Janus kinase/signal transducer of activators of transcription (JAK/STAT) pathway. While JAK inhibitors have shown to alleviate disease symptoms, their disease-modifying effects in MF are limited. The only curative treatment remains allogeneic stem cell transplantation, which can be applied to a minority of patients. As a result
-
Red cell extracellular vesicles and coagulation activation pathways. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-08-03 Denis F Noubouossie, Nigel S Key
Packed red blood cells (PRBCs) are the most commonly transfused blood products. Preparation of PRBCs requires blood collection from donors, processing, and storage prior to transfusion to recipients. Stored red blood cells (RBCs) undergo structural and metabolic changes collectively known as the storage lesion. RBC extracellular vesicles (sREVs) are released in PRBC units during storage, and are transfused
-
Switching and increasing prophylaxis regimen with a genetically recombinant fusion of coagulation factor IX and albumin in haemophilia B: a case report. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-7-31 María Teresa Álvarez-Román, Raquel Díaz Merchán, Roberto Carlos Raynero Mellado, Victor Jiménez-Yuste
We present a case of a boy diagnosed in 2007 with severe haemophilia B [factor IX (FIX) concentration < 1%] at age of 9 months. He was initially treated with recombinant FIX concentrates, but changes in regimens were frequent due to spontaneous hemarthros. In 2013, he entered a phase III trial (NCT01662531) and received rIX-FP, IDELVION at 50 IU/kg once a week. Although the boy was safely maintained
-
Tissue factor positive microparticles as a biomarker for increased risk of breast cancer-associated thrombosis: a mini review. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-7-31 Regan Bucciol, Maha Othman
Cancer-associated thrombosis (CAT), such as venous thromboembolism (VTE), is a frequent complication in cancer patients, resulting in poor prognosis. Breast cancer is not highly thrombogenic but is highly prevalent, resulting in increased VTE cases. Many cancers express tissue factor (TF), a glycoprotein that triggers coagulation. The cancer cells were shown to express and release substantial amounts
-
New insights into the glycobiology of immune thrombocytopenia. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-07-28 Katherine H Tiemeyer, David J Kuter, Christopher W Cairo, Marie A Hollenhorst
The platelet surface harbors a lush forest of glycans (carbohydrate polymers) attached to membrane proteins and lipids. Accumulating evidence suggests that these glycans may be relevant to the pathophysiology of immune thrombocytopenia (ITP). Here, we critically evaluate data that point to a possible role for loss of sialic acid in driving platelet clearance in ITP, comment on the potential use of
-
Warm autoimmune hemolytic anemia: new insights and hypotheses. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-07-28 Donald R Branch
Warm autoimmune hemolytic anemia (wAIHA) is the most common of the immune hemolytic anemias. Although there are numerous case reports and reviews regarding this condition, some of the unusual and more recent findings have not been fully defined and may be contentious. This review will provide insight into the common specificity of the warm autoantibodies and hypothesize a novel mechanism of wAIHA,
-
In-vivo functions and regulation of polyphosphate in the vascular system. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-07-18 Wen-Chan Huang, Reiner K Mailer, Thomas Renné
Polyphosphate, an inorganic polymer consisting of linearly linked phosphate subunits, is ubiquitously found in living organisms. Functions and regulation of the polymer have been analyzed in plants, bacteria and yeast; however, the roles of polyphosphate in mammals are still emerging.
-
Platelet mitochondria: the mighty few. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-07-18 Abigail Ajanel, Robert A Campbell, Frederik Denorme
Platelet mitochondrial dysfunction is both caused by, as well as a source of oxidative stress. Oxidative stress is a key hallmark of metabolic disorders such as dyslipidemia and diabetes, which are known to have higher risks for thrombotic complications.
-
The invisible string of coagulation, complement, iron, and inflammation in sickle cell disease. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-07-15 Joan D Beckman, Erica M Sparkenbaugh
This review provides an update on recent advances in mechanistic studies of thromboinflammatory mechanisms that contribute to the disease pathology in sickle cell disease (SCD). There is a focus on novel pathways, clinical relevance, and translational potential of these findings. We hope to encourage more advances in this area to reduce organ damage in young patients prior to gene therapy, and to serve
-
The impact of prenatal inflammation on hematopoietic development. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-05-09 Nicole A Tseng,Anna E Beaudin
PURPOSE OF REVIEW Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis
-
Interferon regulatory factor-8-dependent innate immune alarm senses GATA2 deficiency to alter hematopoietic differentiation and function. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-04-27 Kirby D Johnson,Mabel M Jung,Vu L Tran,Emery H Bresnick
PURPOSE OF REVIEW Recent discoveries have provided evidence for mechanistic links between the master regulator of hematopoiesis GATA2 and the key component of interferon and innate immunity signaling pathways, interferon-regulatory factor-8 (IRF8). These links have important implications for the control of myeloid differentiation in physiological and pathological states. RECENT FINDINGS GATA2 deficiency
-
Crosstalk between terminal erythropoiesis and granulopoiesis within their common niche: the erythromyeloblastic island. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-04-25 Laurel Romano,Katie G Seu,Lionel Blanc,Theodosia A Kalfa
PURPOSE OF REVIEW The identity of the erythroblastic island (EBI) macrophage (Mϕ) has been under investigation for decades since it was recognized as the first hematopoietic niche 'nursing' terminal erythropoiesis. This review will focus on the current insights to the characteristics and the role of the EBI Mϕ balancing terminal erythropoiesis and granulopoiesis. RECENT FINDINGS While the EBI has long
-
Deficits in our understanding of natural killer cell development in mouse and human. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-04-19 Christopher Schorr, Maya Shraddha Krishnan, Maegan Capitano
Natural killer (NK) cells are a type of immune cell that play a crucial role in the defense against cancer and viral infections. The development and maturation of NK cells is a complex process, involving the coordination of various signaling pathways, transcription factors, and epigenetic modifications. In recent years, there has been a growing interest in studying the development of NK cells. In this
-
Understanding and targeting erythroid progenitor cells for effective cancer therapy. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-04-13 Qingfei Wang, Rylee A Poole, Mateusz Opyrchal
It is well described that tumor-directed aberrant myelopoiesis contributes to the generation of various myeloid populations with tumor-promoting properties. A growing number of recent studies have revealed the importance of the previously unappreciated roles of erythroid progenitor cells (EPCs) in the context of cancer, bringing the updated concept that altered erythropoiesis also facilitates tumor
-
Regulation of granulocyte colony-stimulating factor-induced hematopoietic stem cell mobilization by the sympathetic nervous system. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-04-11 Tomohide Suzuki, Shinichi Ishii, Yoshio Katayama
Granulocyte colony-stimulating factor (G-CSF) is now a standard agent to mobilize hematopoietic stem cells (HSCs) from the bone marrow to circulation. This review introduced mechanistic insights from the aspect of the sympathetic nervous system (SNS).
-
Editorial: Current Opinion in Hematology: new editor announcement. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-05-01 Sarah J Booth
-
Navigating the marrow sea towards erythromyeloblastic islands under normal and inflammatory conditions Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-05-01 Rachel Josselsohn, Betsy J. Barnes, Theodosia A. Kalfa, Lionel Blanc
Purpose of review Terminal erythroid differentiation occurs in specialized niches called erythroblastic islands. Since their discovery in 1958, these niches have been described as a central macrophage surrounded by differentiating erythroblasts. Here, we review the recent advances made in the characterization of these islands and the role they could play in anaemia of inflammation. Recent findings
-
Hidden behind thromboinflammation: revealing the roles of von Willebrand factor in sickle cell disease pathophysiology Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-05-01 Eudorah F. Vital, Wilbur A. Lam
Purpose of review This review provides an update on the pathophysiology of sickle cell disease (SCD) with a particular focus on the dysregulation of the von Willebrand factor (VWF) - ADAMTS13 axis that contributes to its pathogenesis. In discussing recent developments, we hope to encourage new and ongoing discussions surrounding therapeutic targets for SCD. Recent findings Within the last 5 years
-
Erythrocyte pyruvate kinase activation in red cell disorders Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-05-01 Alessandro Matte, Enrica Federti, Lucia De Franceschi
Purpose of review In red cells, pyruvate kinase is a key enzyme in the final step of glycolytic degradative process, which generates a constant energy supply via ATP production. This commentary discusses recent findings on pyruvate kinase activators as new therapeutic option in hereditary red cell disorders such as thalassemic syndromes or sickle cell disease (SCD). Recent findings Mitapivat and
-
Editorial: Molecular advances make the day in myeloid diseases. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-03-01 Stephanie Halene
-
Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-03-01 Giulia Maggioni, Matteo G. Della Porta
Purpose of review The aim of this review is to provide a complete perspective of the evidence that led to the three recent new landmarks of myelodysplastic syndromes (MDS) definition and prognostication: the WHO 2022 and International Consensus Classification (ICC) 2022 classification and the Molecular Intermational Prognostic Scoring System (IPSS-M) score. Recent findings The molecular founding
-
Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemia Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-03-01 Andrew M. Brunner
Purpose of review Therapies that target the immune system are increasingly used across oncology, including in hematologic malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). While allogeneic transplant has been a key therapy in these cancers, new approaches that target the immune system are being explored including immune checkpoint therapies, antibody−drug conjugates
-
Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-03-01 Shivani Handa, Yelena Ginzburg, Ronald Hoffman, Marina Kremyanskaya
Purpose of review Development of hepcidin therapeutics has been a ground-breaking discovery in restoring iron homeostasis in several haematological disorders. The hepcidin mimetic, rusfertide, is in late-stage clinical development for treating polycythemia vera patients with a global phase 3 trial [NCT05210790] currently underway. Rusfertide serves as the first possible noncytoreductive therapeutic
-
The fifth edition of the World Health Organization Classification and the International Consensus Classification of myeloid neoplasms: evolving guidelines in the molecular era with practical implications Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-03-01 Gang Zheng, Peng Li, Xiaohui Zhang, Zenggang Pan
Purpose of review There have been major advances in our understanding of molecular pathogenesis of myeloid neoplasms, which prompt the updates in the classification of myeloid neoplasms in the fifth edition of World Health Organization Classification (WHO-5) and the new International Consensus Classification (ICC). The purpose of this review is to provide an overview of these two classification systems
-
VEXAS: where do we stand 2 years later? Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-03-01 Pierre Sujobert, Maël Heiblig, Yvan Jamilloux
Purpose of review Two years after the recognition of VEXAS (for Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, we propose an extensive review of the current understanding of VEXAS pathophysiology and therapeutic options. Recent findings Among the nearly 150 articles published about VEXAS, some have provided determinant insights into VEXAS pathophysiology and treatment. Clinical
-
Is it the time to integrate novel sequencing technologies into clinical practice? Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-03-01 Jennifer VanOudenhove, Stephanie Halene, Lourdes Mendez
Purpose of review The aim of this study was to provide insight into how novel next-generation sequencing (NGS) techniques are set to revolutionize clinical practice. Recent findings Advances in sequencing technologies have focused on improved capture of mutations and reads and cellular resolution. Both short and long read DNA sequencing technology are being refined and combined in novel ways with
-
Haematopoietic stem cell quiescence exposed using mitochondrial membrane potential Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-01-01 Saghi Ghaffari
Purpose of review Quiescence is a fundamental property of haematopoietic stem cells (HSCs). Despite the importance of quiescence in predicting the potency of HSCs, tools that measure routinely the degree of quiescence or select for quiescent HSCs have been lacking. This Commentary discusses recent findings that address this fundamental gap in the HSC toolbox. Recent findings Highly purified, phenotypically-defined
-
N6-methyladenosine in hematological malignancies: a concise review Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-01-01 Wan-Jie Wang, Ting-Ting Xu, Jing Bao
Purpose of review Hematological malignancies are a kind of systemic cancers mostly related to abnormal differentiation of blood stem cells. Because of the poor prognosis, chemotherapy resistance and common recurrence, new mechanisms and treatment therapies are looking forward to be discovered. Recent findings Over the years, epigenetic abnormalities have been known to act a key part in occurrence
-
Old age: the crown of life, our play's last act. Question and answers on older patients undergoing allogeneic hematopoietic cell transplantation Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-01-01 Enrico Maffini, Moreno Festuccia, Margherita Ursi, Francesco Barbato, Michele Dicataldo, Marcello Roberto, Elena Campanini, Elisa Dan, Francesco De Felice, Serena De Matteis, Gianluca Storci, Massimiliano Bonafè, Mario Arpinati, Francesca Bonifazi
Purpose of review Several studies showed that age alone should not be used as an arbitrary parameter to exclude patients from allogeneic hematopoietic cell transplantation (HCT). The accessibility to allogeneic HCT programs for older patients with hematological diseases is growing up constantly. The Center for International Blood and Marrow Transplant Research has recently shown that over 30% of allogeneic
-
Challenges and opportunities in shared care for international patients treated with cellular therapy for nonmalignant disease Curr. Opin. Hematol. (IF 3.2) Pub Date : 2023-01-01 Syeda A. Mina, Ibrahim N. Muhsen, Shahrukh K. Hashmi
As cellular therapies gradually become the mainstay of treatment for several nonmalignant diseases, there appears to be varied accessibility to these therapies globally. Despite considerable burden of nonmalignant conditions, such as sickle cell disease, thalassemia, and aplastic anemia in populations of low–middle-income countries, the utilization of cellular therapies remain sparse because of lack
-
Novel blood derived hemostatic agents for bleeding therapy and prophylaxis Curr. Opin. Hematol. (IF 3.2) Pub Date : 2022-11-01 Shailaja Hegde, Yi Zheng, Jose A. Cancelas
Purpose of review Hemorrhage is a major cause of preventable death in trauma and cancer. Trauma induced coagulopathy and cancer-associated endotheliopathy remain major therapeutic challenges. Early, aggressive administration of blood-derived products with hypothesized increased clotting potency has been proposed. A series of early- and late-phase clinical trials testing the safety and/or efficacy
-
Hyperviscosity syndromes; hemorheology for physicians and the use of microfluidic devices Curr. Opin. Hematol. (IF 3.2) Pub Date : 2022-11-01 Jamie O. Musick, Kirby S. Fibben, Wilbur A. Lam
Purpose of review Hyperviscosity syndromes can lead to significant morbidity and mortality. Existing methods to measure microcirculatory rheology are not readily available and limited in relevance and accuracy at this level. In this review, we review selected hyperviscosity syndromes and the advancement of their knowledge using microfluidic platforms. Recent findings Viscosity changes drastically
-
Immunologic effects of red blood cell and platelet transfusions in neonates Curr. Opin. Hematol. (IF 3.2) Pub Date : 2022-11-01 Patricia Davenport, Martha Sola-Visner
Purpose of Review Premature neonates are frequently transfused red blood cells (RBCs) or platelets to raise hemoglobin or platelet counts. However, these transfusions may have unintended effects on the immune system. This review will summarize the newest discoveries on the immunologic effects of RBC and platelet transfusions in neonates, and their potential impact on neonatal outcomes. Recent Findings
-
Immunomodulatory roles of red blood cells Curr. Opin. Hematol. (IF 3.2) Pub Date : 2022-11-01 Jane Dobkin, Nilam S. Mangalmurti
Purpose of the Review To discuss recent advances supporting the role of red blood cells (RBCs) in the host immune response Recent Findings Over the last century, research has demonstrated that red blood cells exhibit functions beyond oxygen transport, including immune function. Recent work indicates that the nucleic acid sensing receptor, toll-like receptor 9 (TLR9), is expressed on the RBC surface
-
Iron status of blood donors Curr. Opin. Hematol. (IF 3.2) Pub Date : 2022-11-01 Bryan R. Spencer, Alan E. Mast
Purpose of review This review examines recent research on the prevalence and importance of iron deficiency in blood donors, and on efforts to mitigate it. Recent findings Premenopausal females, teenagers, and high-frequency donors are at the highest risk for donation-induced iron deficiency, in both high-resource and low-resource settings. The physiology relating iron stores to hemoglobin levels
-
Umbilical cord blood: an undervalued and underutilized resource in allogeneic hematopoietic stem cell transplant and novel cell therapy applications Curr. Opin. Hematol. (IF 3.2) Pub Date : 2022-11-01 Patricia A. Shi, Larry L. Luchsinger, John M. Greally, Colleen S. Delaney
Purpose of review The purpose of this review is to primarily discuss the unwarranted decline in the use of umbilical cord blood (UCB) as a source of donor hematopoietic stem cells (HSC) for hematopoietic cell transplantation (HCT) and the resulting important implications in addressing healthcare inequities, and secondly to highlight the incredible potential of UCB and related birthing tissues for
-
Emerging functional microfluidic assays for the study of thromboinflammation in sickle cell disease Curr. Opin. Hematol. (IF 3.2) Pub Date : 2022-11-01 Ran An, Umut A. Gurkan
Purpose of review This review briefly summarizes the significant impact of thromboinflammation in sickle cell disease in relation to recent advances in biomarkers that are used in functional microfluidic assays. Recent findings Sickle cell disease (SCD) is an inherited hemoglobinopathy that affects 100 000 Americans and millions worldwide. Patients with SCD exhibit chronic haemolysis, chronic inflammation
-
Global perspectives on cellular therapy for children with sickle cell disease. Curr. Opin. Hematol. (IF 3.2) Pub Date : 2022-09-21 Tami D John, Ruth Namazzi, Lulu Chirande, Venée N Tubman
Low-income and middle-income countries (LMICs), primarily in sub-Saharan Africa (SSA), predominantly experience the burden of sickle cell disease (SCD). High frequency of acute and chronic complications leads to increased utilization of healthcare, which burdens fragile health systems. Mortality for children with limited healthcare access remains alarmingly high. Cellular based therapies such as allogeneic